Stoke Therapeutics, Inc. (STOK)
30.05
+0.24
(+0.81%)
USD |
NASDAQ |
Sep 08, 16:00
29.60
-0.45
(-1.50%)
After-Hours: 07:28
Stoke Therapeutics Debt to Equity Ratio : 0.0078 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0078 |
| March 31, 2026 | 0.0087 |
| December 31, 2025 | 0.0118 |
| September 30, 2025 | 0.0155 |
| June 30, 2025 | 0.0106 |
| March 31, 2025 | 0.012 |
| December 31, 2024 | 0.0208 |
| September 30, 2024 | 0.0229 |
| June 30, 2024 | 0.024 |
| March 31, 2024 | 0.0452 |
| December 31, 2023 | 0.0428 |
| September 30, 2023 | 0.0192 |
| June 30, 2023 | 0.0206 |
| March 31, 2023 | 0.021 |
| December 31, 2022 | 0.0275 |
| September 30, 2022 | 0.0276 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.0093 |
| March 31, 2022 | 0.0064 |
| December 31, 2021 | 0.0231 |
| September 30, 2021 | 0.0225 |
| June 30, 2021 | 0.005 |
| March 31, 2021 | 0.0001 |
| December 31, 2020 | 0.0003 |
| September 30, 2020 | 0.0073 |
| June 30, 2020 | 0.0082 |
| March 31, 2020 | 0.005 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Biogen, Inc. | 0.4433 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 393.97M |
| Total Liabilities (Quarterly) | 48.42M |
| Shareholders Equity (Quarterly) | 345.55M |
| Current Ratio | 7.692 |
| Net Debt Paydown Yield | 0.02% |